Adlai Nortye (ANL) Liabilities and Shareholders Equity (2022 - 2025)

Adlai Nortye's (ANL) quarterly Liabilities and Shareholders Equity came in at $34.4 million in Q4 2025, down 51.69% year-on-year from $71.3 million in Q4 2024, and down 52.21% on a QoQ basis from $72.0 million in Q2 2025.

Adlai Nortye (ANL) Liabilities and Shareholders Equity (2022 - 2025) Analysis & Trends

Adlai Nortye (ANL) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $34.4 million in Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 51.69% year-over-year to $34.4 million in Q4 2025; TTM through Dec 2025 was $285.4 million, a 25.23% decrease from a year earlier, with the FY2025 full-year figure at $34.4 million, down 51.69% from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 stood at $34.4 million, down from $72.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ANL reached as high as $130.2 million in Q4 2023 and fell as low as $34.4 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $81.4 million across 4 years, with a median of $72.3 million in 2022.
  • Across the five-year window, Liabilities and Shareholders Equity soared 79.34% in 2023 and tumbled 51.69% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $72.6 million in 2022, then jumped by 79.34% to $130.2 million in 2023, then plunged by 45.26% to $71.3 million in 2024, then plunged by 51.69% to $34.4 million in 2025.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $34.4 million in Q4 2025, $72.0 million in Q2 2025, and $71.3 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 311.58 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 78.88 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 33.89 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 8.55 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - 811.27 Mn
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn - 2.25 Bn
10 Adlai Nortye 1.16 Bn 1.15 Bn - 34.43 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 34.43 Mn
Jun 30, 2025 72.05 Mn
Dec 31, 2024 71.27 Mn
Jun 30, 2024 107.68 Mn
Dec 31, 2023 130.19 Mn
Dec 31, 2022 72.59 Mn